组蛋白去乙酰化酶抑制剂治疗非霍奇金淋巴瘤研究进展

Progress of histone deacetylase inhibitors in treatment of non-Hodgkin lymphoma

目前针对复发难治性非霍奇金淋巴瘤(NHL),治疗方案较少且疗效有限。组蛋白去乙酰化酶抑制剂(HDACi)可以通过靶向抑制组蛋白去乙酰化酶(HDAC)活性,调控基因表达,从而发挥抗肿瘤作用。HDACi单药或联合其他抗肿瘤药物治疗复发难治NHL表现出较好的疗效。现就HDACi治疗NHL的进展进行综述。

At present,there are few treatment protocols with limited efficacy for relapsed and refractory non-Hodgkin lymphoma(NHL).Histone deacetylase inhibitors(HDACi)exert anti-tumor effects by inhibiting the activation of histone deacetylase(HDAC)and regulating gene expression.HDACi alone or combined with other anti-tumor drugs have shown good efficacy in the treatment of relapsed and refractory NHL.This article reviews the progress of HDACi in the treatment of NHL.